Breast Cancer, Metastasis, Neoplasm
Conditions
Keywords
metastasis, chemotherapy, breast cancer, Vinorelbine, Capecitabine, sequential chemotherapy, TTF
Brief summary
The primary objective of this study is to evaluate the efficacy and tolerability of sequential use of vinorelbine and capecitabine as first line therapy in patients with MBC.
Detailed description
The administration of vinorelbine and capecitabine had been implied to be quite useful in metastatic breast cancer. This study was designed to explore whether sequential and simultaneous use of vinorelbine and capecitabine have similar efficacy and whether the sequential way has better tolerability.
Interventions
DRUGVinorelbine and Capecitabine
Vinorelbine 25mg/m2 D1, D8 q3w Capecitabine 1000mg/m2 D1-D14 q3w
Sponsors
Fudan University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Signed informed consent. * Female, ≥ 18 and ≤ 70 years. * Histologically confirmed invasive breast cancer. * Metastatic breast cancer. * ECOG Performance Status of 0 to 2. * Life expectancy of more than 3 months. * Subject must have adequate organ function. * Normal laboratory values: hemoglobin \> 90g/dl, neutrophils \> 1.5×10\^9/L, platelets \> 80×10\^9/L, serum creatinine \< 1.5×upper limit of normal (ULN), serum bilirubin \< 1.5×ULN, ALT and AST \< 2.5×ULN. * Negative serum pregnancy test for women with childbearing potential. * Good conditions for infusion and willing to have phlebotomy throughout whole study. * Have ceased anti-tumor treatments including endocrinotherapy and bio-targeted therapy for more than 28 days. * Have at least one target lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
Exclusion criteria
* Pregnant or lactating females * History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible * Concurrent disease or condition that would make the subject inappropriate for study participation, or any serious medical disorder that would interfere with the subject's safety * Active or uncontrolled infection * Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure * Concomitant with brain metastases * Have received chemotherapy after metastasis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS(progression-free survival,defined as the time period between randomization and disease progress or death) and TTF (time to treatment failure, defined as all discontinuations for any cause) | Every two cycles (3 weeks per cycle) and during the follow up time, until disease progression event occurs. | PFS was assessed every two cycles (3 weeks per cycle)and during the follow up time, by serum tumor markers, physical examination and image examination, until disease progression event occurs. If a patient has the sign or hint of disease progression, then the lab examination, physical examination or image examination could be taken at any time. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety, QOL(quality of life) | Safety and QOL were assessed every cycle and during the follow up time, until 28 days after the last cycle. | Safety and QOL were assessed every cycle(3 weeks per cycle) and during the follow up time, until 28 days after the last cycle. |
| TTP(time to progression) and OS (overall survival) | TTP and OS were assessed every cycle and during the follow up time, until the event occurs. | TTP and OS were assessed every cycle(3 weeks per cycle) and during the follow up time, until the event occurs. |
Countries
China
Outcome results
None listed